menopause glp 1 GLP-1 Microdosing for Perimenopause and Menopause: A Hormone-Aware Metabolic Framework Menopause Hormone Therapy Boosts GLP-1

Sleep Apnea and Kidney Disease Separate ongoing TRIUMPH Phase 3 trials are evaluating retatrutide in patients with moderate-to-severe obstructive sleep apnea and in adults with chronic kidney disease and obesity

Clin Nutr Edinb Scotl

While the outcomes from the clinical trials regarding the therapeutic potential of GLP-1RAs (and DPP-4 inhibitors) in AD and PD are eagerly anticipated in the near future (Table 2), some additional considerations are worth pointing out for the transition into the clinical setting

Inclusion criteria for the patients in this study included age between 18 and 65 years and a diagnosis of primary polydipsia based on polydipsia of greater than 3000 mL per day and polyuria of greater than 50 mL/kg body weight per day

In T2DM, they are typically recommended as second-line or add-on therapymost often after metformin failureand more recently as first-line agents in people with established cardiovascular or renal disease [15, 16]